The Vetoquinol Group has reported sales of €350.3 million for 2016, representing like-for-like growth of 4.3%.
Sales of reference products amounted to €170.9 million (48.8% of 2016 sales).
Growth was driven by strong performances in the Americas and Asia Pacific, which posted respective like-for-like growth rates of 9.2% and 12.7%. Sales in Europe fell 1.0% (like-for-like) in 2016, with new product launches failing to fully offset the negative impact related to antibiotics, said the company in its press release.
Vetoquinol CEO Matthieu Frechin commented: “In 2016 we posted organic growth in line with our ambitions, thus confirming the merits of our focusing strategy that combines rebalancing our product portfolio in terms of therapeutic segments with international expansion in our strategic countries. Backed by a strong financial structure, we are stepping up our efforts in innovation and new product launches, while working systematically on targeted acquisition opportunities”.